# Sartorius shows demand recovery with stronger cash conversion

> Constraint Alpha research note. Confidence: medium.

Published: 2026-10-26T05:39:16Z  
Research as of: 2026-10-26  
Scope: company / Sartorius (SRT)

## Summary

Sartorius reported 8.1% constant-currency operational sales growth excluding U.S. tariff compensation for the first nine months of 2026, alongside a 55.2% increase in free cash flow.

## What changed

- Recurring consumables remained a growth driver while bioprocess equipment and instrument demand continued to recover.
- Underlying EBITDA margin rose 0.5 percentage points to 30.2%; operating cash flow increased 9.9% and free cash flow reached €310 million as investment declined.

## Why it matters

The combination of demand recovery, margin and cash is stronger conversion evidence than a product-capability page. It still does not isolate qualified bioprocess throughput or AI-specific revenue.

## Evidence

- [Sartorius: nine-month 2026 results](https://www.sartorius.com/en/company/newsroom/corporate-news/2026-nine-month-results-sartorius-group-1886514) — Operational sales growth, margin, cash flow, investment and demand commentary. (as of 2026-10-22)

Member-only thesis, risk, catalyst, falsification, and score fields are intentionally excluded.  
Canonical URL: https://constraintalpha.com/research/sartorius-nine-month-conversion-2026